Your browser doesn't support javascript.
loading
Holmium laser ablation of the prostate (HoLAP) with moses technology for the surgical treatment of benign prostatic hyperplasia
Grosso, Antonio Andrea; Maida, Fabrizio Di; Mari, Andrea; Nardoni, Samuele; Tuccio, Agostino; Minervini, Andrea.
  • Grosso, Antonio Andrea; University of Florence. Department of Experimental and Clinical Medicine. Unit of Oncologic Minimally-Invasive Urology and Andrology. Florence. IT
  • Maida, Fabrizio Di; University of Florence. Department of Experimental and Clinical Medicine. Unit of Oncologic Minimally-Invasive Urology and Andrology. Florence. IT
  • Mari, Andrea; University of Florence. Department of Experimental and Clinical Medicine. Unit of Oncologic Minimally-Invasive Urology and Andrology. Florence. IT
  • Nardoni, Samuele; University of Florence. Department of Experimental and Clinical Medicine. Unit of Oncologic Minimally-Invasive Urology and Andrology. Florence. IT
  • Tuccio, Agostino; University of Florence. Department of Experimental and Clinical Medicine. Unit of Oncologic Minimally-Invasive Urology and Andrology. Florence. IT
  • Minervini, Andrea; University of Florence. Department of Experimental and Clinical Medicine. Unit of Oncologic Minimally-Invasive Urology and Andrology. Florence. IT
Int. braz. j. urol ; 48(1): 200-201, Jan.-Feb. 2022.
Article in English | LILACS | ID: biblio-1356299
Responsible library: BR1.1
ABSTRACT
ABSTRACT

Purpose:

The expansion of technology is leading to a paradigm shift in several urological fields (1, 2). In particular, the adoption of lasers within the surgical treatment of patients with benign prostatic hyperplasia (BPH) is considered one of the most relevant innovations (3-5). In this video, we aimed to report our experience with holmium laser for the ablation of the prostate (HoLAP) in patients with obstructive lower urinary tract symptoms (LUTS) due to BPH. Materials and

Methods:

From 2018 to 2020, 10 patients with obstructive LUTS secondary to BPH were treated at our Institution with HoLAP (120W Holmium laser Lumenis® with Moses® technology). Main inclusion criteria were 1) International Prostate Symptom Score ≥12; 2) prostate volume ≤65mL, 3) maximal flow rate (Qmax) ≤15ml/s at preoperative non-invasive uroflowmetry.

Results:

Mean patient age was 65 (range 59-72) years. Preoperative mean prostate volume was 50 (range 35-65) mL. Mean operative time was 66 (range 45-85) minutes with a mean laser time/operative time ratio of 0.51 (range 0.44-0.60). Voiding symptoms, Qmax and post voiding residual were significantly improved after 3 and 12 months (all p <0.05). No postoperative urinary incontinence was detected.

Conclusions:

The present findings suggest that HoLAP is a slightly time-spending procedure, thus its use should be limited to prostate volume <70-80mL. However, no postoperative complications were recorded at all. This technique showed to be a safe option in patients with low-intermediate prostate volume, also in patients whose antiaggregant/anticoagulant therapy is maintained.
Subject(s)

Full text: Available Index: LILACS (Americas) Main subject: Prostatic Hyperplasia / Transurethral Resection of Prostate / Laser Therapy / Lasers, Solid-State Limits: Humans / Male Language: English Journal: Int. braz. j. urol Journal subject: Urology Year: 2022 Type: Article Affiliation country: Italy Institution/Affiliation country: University of Florence/IT

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Index: LILACS (Americas) Main subject: Prostatic Hyperplasia / Transurethral Resection of Prostate / Laser Therapy / Lasers, Solid-State Limits: Humans / Male Language: English Journal: Int. braz. j. urol Journal subject: Urology Year: 2022 Type: Article Affiliation country: Italy Institution/Affiliation country: University of Florence/IT